PO.CL11.02 · 临床研究

癌症后健康综合结局(COACH)研究:晚期癌症个体基线人口学与患者报告结局数据的中期分析

The comprehensive outcomes for after cancer health (COACH) study: Interim analysis of baseline demographic and patient reported outcome data for individuals with advanced cancer

编号 1246 展板 20 时间 4/19 02:00–05:00 区域 Section 48 主讲 Kelly Brassil, BA;MA;MSN;PhD;RN
分会场 Survivorship, Supportive Care, and Quality of Life in Oncology
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Kelly J. Brassil1, Trudy Buckingham2, Anneliese Gonzalez3, Michael Harrison4, Kaukab Jafry3, Abbey Kaler5, Hilda H. Lewis6, Jennifer Loftis4, Kathrin Milbury7, Darcy Ponce8, Michelle Schumacher6, Meagan Whisenant8, Cosmina Hogea2

1Medical Affairs, Quest Diagnostics, Houston, TX,2Gilead Sciences, Foster City, CA,3UT Health Houston, Houston, TX,4Medical Affairs, Quest Diagnostics, Secaucus, NJ,5Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,6Radiation Oncology, Montefiore Medical Center, Bronx, NY,7Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX,8UT Health Houston Cizik School of Nursing, Houston, TX

摘要 Abstract

中文摘要
背景:转移性癌症患者面临复杂的自我管理挑战,需要症状监测、护理协调及社会心理支持。数字工具,包括电子患者报告结局(ePRO)、可穿戴设备和健康指导(DHC),已被证明能改善结局,包括癌症个体的总生存期,然而对于晚期乳腺癌(aBC)或肺癌(aLC)个体的作用了解较少。COACH试验(NCT05349227)评估一项综合DHC项目,该项目结合临床、ePRO、可穿戴设备和肠道微生物组数据,以满足这些特殊群体的生存需求。 方法:这项多中心、随机、等待名单对照试验在8个中心招募675名成年人(≥18岁),入组条件为完成初始治疗后一年内或患有转移性疾病。亚群包括aBC(n=150)和aLC(n=100)。参与者被随机分配至6个月的DHC组或对照组,并在第6个月交叉。所有参与者均配备活动追踪器(Fitbit),在12个月的过程中完成ePRO,并在基线和第6个月提供粪便微生物组标本及饮食数据。 中期结局:截至2025年11月,已招募91名aBC参与者,其中75名已完成基线ePRO评估,41.5%已将其Fitbit设备连接至云端以进行数据收集。表中呈现了61名有可分析数据的参与者的基线PROMIS评分。 结论:中期数据提示,转移性癌症个体在数值上具有更高的焦虑水平以及更低的认知和身体功能,与人群平均评分相比。本研究的结局将评估DHC能否以及如何用于应对这些挑战。本研究所得的多模态数据旨在增进对晚期癌症个体潜在独特生存需求的理解。 表. 已知情同意参与者的人口学数据及美国国立卫生研究院工具的平均基线评分 人口学数据(n=75) 均值(SD)/n(%) 年龄 57.09 (12.65) 性别 女性:75 (100%) 种族与族裔(参与者可选择≥1项) 亚裔 3 (4.0%) 黑人或非裔美国人 17 (22.7%) 白人 43 (57.3%) 西班牙裔或拉丁裔 17 (22.7%) 非西班牙裔/拉丁裔 58 (77.3%) 多族裔/其他 6 (8%) 不愿回答 6 (8%) 就业状况 全职 26 (34.7%) 兼职 4 (5.3%) 家庭主妇 5 (6.7%) 退休 19 (25.3%) 病假 2 (2.7%) 因病致残 12 (16%) 失业 4 (5.3%) 未知 3 (4%) 患者报告结局测量信息系统(PROMIS)工具 基线评分(n)* 平均评分(SD;范围;癌症个体人群平均值) 焦虑 (60) 53.1 (9.1; 37.1-75.1; 50.6) 认知功能 (61) 46.8 (9.4; 24.4-63.9; 49.9) 抑郁 (61) 49.8 (8.5; 38.2-74.3; 50-53) 身体功能 (61) 43.6 (8.7; 25.2-61.9; 46.1)
查看英文原文 English abstract
Background: Patients with metastatic cancer face complex self-management challenges requiring symptom monitoring, care coordination, and psychosocial support. Digital tools, including electronic patient-reported outcomes (ePROs), wearables, and health coaching (DHC), have demonstrated improvement outcomes, including overall survival for individuals with cancer, yet less is known about their effect for individuals with advanced breast (aBC) or lung(aLC) cancer. The COACH trial (NCT05349227) evaluates a comprehensive DHC program combining clinical, ePRO, wearable, and gut microbiome data to address survivorship needs in these unique groups. Methods: This multicenter, randomized, wait-list controlled trial enrolls 675 adults (≥18 years) within one year of completing primary therapy or with metastatic disease, across 8 sites. Subpopulations include aBC (n=150) and aLC (n=100). Participants are randomized to 6 months of DHC or control, with crossover at month 6. All participants are provided with activity trackers (Fitbit), complete ePROs over the course of 12 months, and provide fecal microbiome specimens and dietary data at baseline and month 6. Interim Outcomes: As of November 2025, 91 aBC participants have been enrolled, of whom 75 have completed baseline ePRO assessments, and 41.5% have connected their Fitbit device to the cloud for data collection. Baseline PROMIS scores for 61 participants with data available for analysis are presented in the Table. Conclusion: Interim data suggest that individuals with metastatic cancer have numerically higher anxiety and lower cognitive and physical functioning compared to population mean scores. Outcomes from this study will evaluate if and how DHC can be used to address these challenges. Multimodal data derived from this study is intended to enhance understanding of the potentially unique survivorship needs of individuals with advanced cancer. Table. Consented Participant Demographic Data and Mean Baseline Scores for The National Institutes o Demographic Data (n=75) Mean (SD)/n(%) Age 57.09 (12.65) Sex Female: 75 (100%) Race and Ethnicity (Participants could select >/= 1 response) Asian 3 (4.0%) Black or African American 17 (22.7%) White 43 (57.3%) Hispanic or Latino 17 (22.7%) Not Hispanic/Latino 58 (77.3%) Multiethnic/Other 6 (8%) Prefer not to answer 6 (8%) Employment Status Full time 26 (34.7%) Part time 4 (5.3%) Homemaker 5 (6.7%) Retired 19 (25.3%) Medical leave of absence 2 (2.7%) Disabled due to illness 12 (16%) Unemployed 4 (5.3%) Unknown 3 (4%) Patient Reported Outcomes Measurement Information System (PROMIS) Tool Baseline Scores (n)* Mean Score (SD; Range; Population average for individuals with cancer ) Anxiety (60) 53.1 (9.1; 37.1-75.1; 50.6 ) Cognitive Function (61) 46.8 (9.4; 24.4-63.9; 49.9 ) Depression (61) 49.8 (8.5; 38.2-74.3; 50-53 ) Physical Function (61) 43.6 (8.7; 25.2-61.9; 46.1 )
利益披露 Disclosure
K. J. Brassil, Quest Diagnostics Employment, Stock Option. Gilead Sciences ). GSK ). Sanofi ). Novartis ). T. Buckingham, Gilead Sciences Employment. A. Gonzalez, Gilead Sciences ). M. Harrison, Quest Diagnostics Employment. K. Jafry, None.. A. Kaler, None. H. H. Lewis, Gilead Sciences ). Pack Health, A Quest Diagnostics Company ). J. Loftis, Quest Diagnostis Employment. K. Milbury, Gilead Sciences ). D. Ponce, None.. M. Schumacher, None. M. Whisenant, Gilead Sciences ). Pack Health, A Quest Diagnostics Company ). C. Hogea, Gilead Sciences Employment.

← 返回 AACR 2026 检索